
Investments
3Portfolio Exits
3Partners & Customers
10Service Providers
2About Allergan
Allergan is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. On June 25, 2019, Allergan was acquired by AbbVie.

Want to inform investors similar to Allergan about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Allergan
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Allergan in 4 Expert Collections, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
237 items
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Diabetes
1,903 items
Medical Devices
3,607 items
Companies that received FDA De Novo clearances since 2010. Companies tagged as #FDADeNovos
Latest Allergan News
Jan 26, 2023
News provided by Share this article Share this article Industry Outlook The Intravitreal injectables market will be showcasing stable growth at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2022 to 2030. According to the statistics provided by World Health Organization (WHO) approximately 1.3 billion people throughout the globe are suffering with some form of blindness caused majorly due to macular degeneration, diabetic retinopathy, ocular vein occlusions, endophthalmitis and retinitis. Intravitreal injections are being preferred over other treatment options for treating disease associated visual impairment. Rising prevalence of diabetes and increasing geriatric population drive growth As per the research citing of the Lancet journal the global prevalence rate of any age related macular degeneration is 8.69% with a higher prevalence rate in the Caucasian population followed by mongoloids. The primary factors that increase the risk factor for occurrence of macular degeneration are increasing geriatric population, smoking, obesity, genetic, diabetes etc. Diabetic retinopathy is a secondary disease manifestation occurring in elderly people having previous history of diabetes. Endophthalmitis is growing at faster rate owing to rise in air and water pollution and eye trauma. Excellent biocompatibility and impressive pharmacodynamic properties drive the anti-VEGF drugs market Anti-VEGF is dominating the drug class segment for Intravitreal injections market. Since its commercialization in 2006 drugs such as bevacizumab (Avastin), ranibizumab (Lucentis) etc. are considered as the first line drug therapy in patients suffering with neovascular age related macular degeneration and ocular vein occlusion. Its inherent features such as excellent biocompatibility and impressive pharmacodynamic properties has led to its increased popularity among ophthalmologist worldwide. Corticosteroids are used as an adjuvant drug therapy in alleviating inflammation caused due to eye infections. Antifungal drugs and antibiotics together are prescribed in eye infections such as endophthalmitis and retinitis. Rising prevalence of eye disorders and affordable reimbursement scenario drive the Intravitreal injectables market growth In the present situation North America is accountable for 37% market share in the regional segment for Intravitreal injectables market. As per the statistics provided by the Center for Disease Control and Prevention (CDC), approximately 3.3 million Americans aged 40 years and older are blind or suffering with low vision. Rising prevalence of eye disorders and affordable reimbursement scenario drive the market growth in North America. Europe represents 26% share on account of the presence of thriving healthcare infrastructure and domicile of key players such as Novartis AG, Allergan, Inc., Alimera Sciences, F.Hoffman-La Roche Ltd. etc. propel the market growth in Europe. Asia Pacific is holding 20% market share and is keen to capture the regional market in the near future on account of supportive regulatory environment provided by healthcare agencies and developing ophthalmic research centers providing optimum eye care. Pharmaceutical giants competing to maintain stronghold in intravitreal injectables market are Allergan, Inc., Genetech, Inc., Alimera Sciences, Bristol-Myers Squibb Company, Eyetech, Inc., F.Hoffman-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., ThromboGenics, Inc. and Valeant Pharmaceuticals International, Inc. Market Segmentation Key questions answered in this report What are the key micro and macro environmental factors that are impacting the growth of Intravitreal Injectables market? What are the key investment pockets with respect to product segments and geographies currently and during the forecast period? Estimated forecast and market projections up to 2030. Which segment accounts for the fastest CAGR during the forecast period? Which market segment holds a larger market share and why? Are low and middle-income economies investing in the Intravitreal Injectables market? Which is the largest regional market for Intravitreal Injectables market? What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa? Which are the key trends driving Intravitreal Injectables market growth? Who are the key competitors and what are their key strategies to enhance their market presence in the Intravitreal Injectables market worldwide? Key Topics Covered:
Allergan Investments
3 Investments
Allergan has made 3 investments. Their latest investment was in Stemson Therapeutics as part of their Seed VC on September 9, 2020.

Allergan Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/16/2020 | Seed VC | Stemson Therapeutics | $7.5M | Yes | Allergan, and Fortunis Capital | 2 |
1/10/2017 | Series A - II | |||||
10/14/2010 | Series C |
Date | 9/16/2020 | 1/10/2017 | 10/14/2010 |
---|---|---|---|
Round | Seed VC | Series A - II | Series C |
Company | Stemson Therapeutics | ||
Amount | $7.5M | ||
New? | Yes | ||
Co-Investors | Allergan, and Fortunis Capital | ||
Sources | 2 |
Allergan Portfolio Exits
3 Portfolio Exits
Allergan has 3 portfolio exits. Their latest portfolio exit was Anda on August 02, 2016.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
8/2/2016 | Divestiture | Anda | 4 | ||
Date | 8/2/2016 | ||
---|---|---|---|
Exit | Divestiture | ||
Companies | Anda | ||
Valuation | |||
Acquirer | |||
Sources | 4 |
Allergan Acquisitions
37 Acquisitions
Allergan acquired 37 companies. Their latest acquisition was Luminera - Dermal Filler Business on October 07, 2020.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
10/7/2020 | Acquired Unit | 1 | ||||
3/26/2019 | Private Equity | Acquired | 1 | |||
9/14/2018 | Series C | $38.04M | Acquired | 1 | ||
2/7/2018 | Grant | |||||
12/13/2017 |
Date | 10/7/2020 | 3/26/2019 | 9/14/2018 | 2/7/2018 | 12/13/2017 |
---|---|---|---|---|---|
Investment Stage | Private Equity | Series C | Grant | ||
Companies | |||||
Valuation | |||||
Total Funding | $38.04M | ||||
Note | Acquired Unit | Acquired | Acquired | ||
Sources | 1 | 1 | 1 |
Allergan Partners & Customers
10 Partners and customers
Allergan has 10 strategic partners and customers. Allergan recently partnered with Eurobio Scientific on October 10, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
10/6/2021 | Licensor | France | Eurobio Scientific Receives a $430,000 Milestone Payment From Allergan Hervé Duchesne de Lamotte , Deputy General Manager of Eurobio Scientific says : `` Eurobio Scientific 's therapeutics program lives on , thanks to its longtime partner Allergan . | 1 | |
1/5/2021 | Licensor | Japan | Sosei Heptares To Regain Worldwide Rights To Muscarinic Agonist Programs We have established partnerships with some of the world 's leading pharmaceutical companies , including AbbVie , AstraZeneca , Biohaven , Genentech , GSK , Novartis , Pfizer and Takeda and additionally with multiple emerging technology companies . | 3 | |
6/18/2020 | Licensor | United States | AbbVie nixes microbiome GI program collaboration with Assembly Biosciences Assembly Biosciences announces that it has regained global rights to all microbiome gastrointestinal programs out-licensed to AbbVie unit Allergan in January 2017 . | 1 | |
5/8/2020 | Partner | ||||
3/4/2020 | Licensor |
Date | 10/6/2021 | 1/5/2021 | 6/18/2020 | 5/8/2020 | 3/4/2020 |
---|---|---|---|---|---|
Type | Licensor | Licensor | Licensor | Partner | Licensor |
Business Partner | |||||
Country | France | Japan | United States | ||
News Snippet | Eurobio Scientific Receives a $430,000 Milestone Payment From Allergan Hervé Duchesne de Lamotte , Deputy General Manager of Eurobio Scientific says : `` Eurobio Scientific 's therapeutics program lives on , thanks to its longtime partner Allergan . | Sosei Heptares To Regain Worldwide Rights To Muscarinic Agonist Programs We have established partnerships with some of the world 's leading pharmaceutical companies , including AbbVie , AstraZeneca , Biohaven , Genentech , GSK , Novartis , Pfizer and Takeda and additionally with multiple emerging technology companies . | AbbVie nixes microbiome GI program collaboration with Assembly Biosciences Assembly Biosciences announces that it has regained global rights to all microbiome gastrointestinal programs out-licensed to AbbVie unit Allergan in January 2017 . | ||
Sources | 1 | 3 | 1 |
Allergan Service Providers
2 Service Providers
Allergan has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor | |
Service Provider | ||
---|---|---|
Associated Rounds | Acq - P2P | |
Provider Type | Investment Bank | |
Service Type | Financial Advisor |
Partnership data by VentureSource
Compare Allergan to Competitors
Healios provides patients and doctors with mobile health platforms and Digital Biomarkers to improve patient diagnosis and treatment, research and clinical practice. Healios was founded in 2012 and is based in Basel, Switzerland.
Immunwork is a pharmaceutical company that focuses on the research, development, and commercialization of new drugs based on its technology platform for treating multiple types of cancer, autoimmune diseases, osteoporosis, and other severe clinical conditions.

Sumitovant is a biopharmaceutical group focused on improving drug development. The company offers a tech-enabled approach to drug discovery, development and commercialization. It was founded in New York, New York.

Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.

Vivante Health offers an all-in-one digital program for digestive health and disease. GIThrive is its multidisciplinary program that brings together, in one place, everything necessary to manage gut trouble. GIThrive is an employer- and health plan-sponsored digestive health program featuring personalized nutrition plans, daily health challenges, "Med-ucation" to encourage prescription adherence, and on-demand care to address symptom flares and pain with 24/7 Gut-Side Assistance. It was founded in 2016 and is based in Chicago, Illinois.

Ybrain is a brain science healthcare company that commercializes home-based neuropsychiatry diagnosis, treatment, and management solutions for people with mental illnesses. The company's products include MINDD STIM, a medical-grade, noninvasive brain stimulation system that uses weak currents to stimulate the human brain and help patients suffering from mental health conditions such as depression; and MINDD SCAN, a wireless EEG system that allows operators to quickly complete preparation and collection of EEG signals.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.